QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023
QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer
QSAM Biosciences Receives Patents in Japan and Canada; Strengthens Licensed IP Portfolio in Key Markets
QSAM Biosciences Issues Letter from CEO on Successful Achievements and Future Milestones for Company
QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer Therapy
QSAM Biosciences Clarifies Recent Promotional and Trading Activities at the Request of OTC Markets